Bleomycin A5 (hydrochloride) (Synonyms: Pingyangmycin) |
Katalog-Nr.GC10909
One-Click Copy Product Info
|
Bleomycin A5 (Pingyangmycin)-Hydrochlorid ist ein antineoplastisches Glykoprotein-Antibiotikum.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 55658-47-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Bleomycin A5 (hydrochloride) is a glycopeptide antibiotic that acts as the antitumor agent [1]. Bleomycin A5 acts on S stage of cell cycle to snip DNA chain during cell mitosis and disturb the cell proliferation[2]. Bleomycin A5 has been widely used to establish rat models of pulmonary fibrosis and to increase the serum levels of inflammatory cytokines[3].
In vitro, Bleomycin A5 treatment for 72 hours significantly inhibited the viability of nasal polyp-derived fibroblasts (NPDFs), with an IC50 value of 132μM[4]. Treatment with 15μg/ml Bleomycin A5 for 24 hours can increase the levels of caspase-3 and p53, inhibit telomerase activity, and induce apoptosis in ECV304 cells[5]. Treatment with 80μg/ml Bleomycin A5 for 24 hours can induce the expression of p21 in A549 cells, inhibit the expression and phosphorylation of EGFR, and cause cell cycle arrest[6].
In vivo, intratracheal administration of a single dose of Bleomycin A5 (5mg/kg) significantly induced lung inflammation and fibrosis in rats over a period of seven days[7].
References:
[1] Dorr R T, Meyers R, Snead K, et al. Analytical and biological inequivalence of two commercial formulations of the antitumor agent bleomycin[J]. Cancer chemotherapy and pharmacology, 1998, 42(2): 149-154.
[2] Luo Q, Zhao F. The effects of Bleomycin A5 on infantile maxillofacial haemangioma[J]. Head & face medicine, 2011, 7(1): 11.
[3] Wang A, Wang F, Yin Y, et al. Dexamethasone reduces serum level of IL-17 in Bleomycin-A5-induced rats model of pulmonary fibrosis[J]. Artificial Cells, Nanomedicine, and Biotechnology, 2018, 46(4): 783-787.
[4] Wu F, Tian P, Ma Y, et al. Induction of apoptosis in nasal polyp-derived fibroblasts by bleomycin A5 in vitro[J]. Molecular Medicine Reports, 2018, 17(4): 5384-5389.
[5] Huang Y D, Li P, Tong X, et al. Effects of bleomycin A5 on caspase-3, P53, bcl-2 expression and telomerase activity in vascular endothelial cells[J]. Indian Journal of Pharmacology, 2015, 47(1): 55-58.
[6] He Y, Lan Y, Liu Y, et al. Pingyangmycin and bleomycin share the same cytotoxicity pathway[J]. Molecules, 2016, 21(7): 862.
[7] Pan J B, Hou Y H, Zhang G J. Rolipram attenuates bleomycin A5‐induced pulmonary fibrosis in rats[J]. Respirology, 2009, 14(7): 975-982.
| Cell experiment [1]: | |
Cell lines | Nasal polyp‑derived fibroblasts (NPDFs) |
Preparation Method | NPDFs were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin at 37℃ in the presence of 5% CO2. Cultured NPDFs (1×104) were seeded in each well of a 96-well plate in triplicate. After attachment, the cells were treated with Bleomycin A5 at different concentrations (0, 50, 100, 200, 300, and 400µM) for 24, 48, and 72h, then analyzed the cell viability. |
Reaction Conditions | 0, 50, 100, 200, 300, and 400µM; 24, 48, and 72h |
Applications | Bleomycin A5 treatment significantly reduced the cell viability of NPDFs in a concentration and time-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Wistar rats |
Preparation Method | Male Wistar rats (200-220g) were housed in temperature (23±2°C) and light-controlled (12:12-hour light-dark cycle) animal care facility with food and tap water ad libitum. Rats were administered a single dose of Bleomycin A5 (5mg/kg) intratracheally. The sham group were administered the same volume of saline intratracheally, and both groups were injected intraperitoneally with 2.5% ethanol. Day 0 was defined as the day on which Bleomycin A5 was injected. On day 7, 1ml of 10% buffered formaldehyde was perfused into the lung via an intratracheal cannula, and the whole lungs were excised and fixed in 10% buffered formaldehyde. The fixed lungs were embedded in paraffin, stained with HE and Masson's trichrome. |
Dosage form | 5mg/kg for once; intratracheal administration |
Applications | Bleomycin A5 treatment induced lung inflammation and fibrosis in rats. |
References: | |
| Cas No. | 55658-47-4 | SDF | |
| Überlieferungen | Pingyangmycin | ||
| Chemical Name | N1-[3-[(4-aminobutyl)amino]propyl]-bleomycinamide, hydrochloride | ||
| Canonical SMILES | CC(C(N1)=N)=C(N=C1[C@](NC[C@@](N)([H])C(O)=N)([H])CC(O)=N)/C(O)=N/[C@@](/C(O)=N/[C@]([C@](O)([H])[C@@](/C(O)=N/[C@@](/C(O)=N/CCC2=NC(C3=NC(/C(O)=N/CCCNCCCCN)=CS3)=CS2)([H])[C@@](O)([H])C)([H])C)([H])C)([H])[C@](O[C@@]4([H])[C@](O[C@]5([H])[C@](O)([H])[C@] | ||
| Formula | C57H89N19O21S2 • XHCl | M.Wt | 1477 |
| Löslichkeit | DMSO: 0.1 mg/mL,PBS (pH 7.2): 10 mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 677 μL | 3.3852 mL | 6.7705 mL |
| 5 mM | 135.4 μL | 677 μL | 1.3541 mL |
| 10 mM | 67.7 μL | 338.5 μL | 677 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >85.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)